Profile data is unavailable for this security.
About the company
Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.
- Revenue in USD (TTM)2.72bn
- Net income in USD258.26m
- Incorporated1947
- Employees11.50k
- LocationRevvity Inc77 4Th AvenueWALTHAM 02451United StatesUSA
- Phone+1 (781) 663-6900
- Websitehttps://www.revvity.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bruker Corp | 3.24bn | 304.90m | 8.52bn | 9.71k | 27.11 | 4.72 | 18.05 | 2.63 | 2.07 | 2.07 | 21.89 | 11.92 | 0.6527 | 1.51 | 5.73 | 333,913.70 | 6.12 | 8.38 | 8.14 | 11.40 | 49.31 | 49.85 | 9.38 | 11.39 | 0.7085 | 26.83 | 0.5549 | 9.81 | 17.14 | 9.36 | 44.03 | 18.91 | 16.79 | 4.56 |
| Teleflex Inc | 3.03bn | 238.01m | 8.85bn | 14.50k | 37.80 | 1.98 | 17.53 | 2.93 | 5.04 | 5.03 | 64.01 | 96.50 | 0.404 | 2.11 | 6.76 | 208,677.50 | 3.18 | 5.86 | 3.46 | 6.42 | 55.99 | 54.43 | 7.87 | 14.62 | 1.39 | 6.61 | 0.2818 | 15.84 | 6.57 | 3.97 | -1.47 | 12.73 | 2.51 | 0.00 |
| Masimo Corp | 2.04bn | 78.60m | 9.05bn | 3.80k | 116.32 | 6.18 | 52.25 | 4.43 | 1.45 | 1.45 | 37.72 | 27.35 | 0.6715 | 1.77 | 5.52 | 537,526.30 | 2.58 | 8.65 | 3.23 | 10.31 | 50.05 | 57.30 | 3.85 | 12.03 | 1.11 | 2.84 | 0.3456 | 0.00 | 0.6042 | 19.00 | -43.21 | -15.96 | 31.06 | -- |
| Bio Rad Laboratories Inc | 2.58bn | -778.69m | 9.16bn | 8.03k | -- | 1.22 | -- | 3.55 | -27.32 | -27.32 | 90.77 | 267.46 | 0.2294 | 1.49 | 5.61 | 321,321.20 | -6.92 | 9.08 | -7.26 | 9.60 | 54.43 | 55.55 | -30.18 | 41.97 | 4.52 | 0.2612 | 0.1383 | 0.00 | -4.67 | 3.13 | 82.43 | -- | 3.83 | -- |
| Henry Schein, Inc. | 12.50bn | 314.00m | 9.20bn | 25.00k | 30.21 | 2.64 | 15.54 | 0.7359 | 2.44 | 2.44 | 96.89 | 27.99 | 1.22 | 4.77 | 7.73 | 499,960.00 | 2.97 | 6.09 | 4.86 | 10.44 | 31.59 | 30.04 | 2.42 | 4.40 | 0.817 | 6.23 | 0.348 | 0.00 | -2.44 | 5.55 | -22.68 | -0.1456 | 21.27 | -- |
| Penumbra Inc | 1.16bn | 34.55m | 9.23bn | 4.20k | 279.56 | 8.35 | 151.56 | 7.93 | 0.8602 | 0.8602 | 29.71 | 28.78 | 0.7897 | 1.04 | 6.08 | 277,089.50 | 2.34 | 2.32 | 2.61 | 2.61 | 65.70 | 63.90 | 2.97 | 3.17 | 3.25 | -- | 0.0218 | 0.00 | 24.95 | 18.93 | 4,643.16 | 68.60 | 9.64 | -- |
| Solventum Corp | 8.22bn | 720.00m | 12.03bn | 22.01k | 16.72 | 3.77 | 9.51 | 1.46 | 4.16 | 4.16 | 47.45 | 18.48 | 0.5831 | 3.93 | 7.19 | 373,290.30 | 5.11 | -- | 6.03 | -- | 56.38 | -- | 8.76 | -- | 0.8268 | 5.02 | 0.7176 | -- | 0.8241 | -- | 0.2234 | -- | -- | -- |
| Globus Medical Inc | 2.48bn | 91.51m | 13.47bn | 5.00k | 127.95 | 2.84 | 38.50 | 5.43 | 0.6636 | 0.6636 | 18.08 | 29.94 | 0.4747 | 1.28 | 4.58 | 495,719.20 | 1.75 | 6.90 | 1.99 | 7.45 | 58.14 | 71.73 | 3.69 | 14.05 | 1.64 | -- | 0.0974 | 0.00 | 53.34 | 17.08 | -35.39 | -4.72 | 5.57 | -- |
| Revvity Inc | 2.72bn | 258.26m | 13.52bn | 11.50k | 53.04 | 1.71 | 19.69 | 4.97 | 2.09 | 2.06 | 22.06 | 64.88 | 0.2078 | 2.89 | 4.37 | 236,657.00 | 1.97 | 4.76 | 2.15 | 5.39 | 55.44 | 57.19 | 9.49 | 15.34 | 2.97 | 11.96 | 0.2869 | 6.52 | -16.95 | -0.1982 | -64.99 | -5.28 | -2.69 | 0.00 |
| Avantor Inc | 6.82bn | 309.60m | 13.86bn | 14.50k | 44.81 | 2.50 | 19.39 | 2.03 | 0.4544 | 0.4544 | 10.01 | 8.16 | 0.532 | 5.56 | 6.09 | 470,331.00 | 2.42 | 2.97 | 2.75 | 3.35 | 33.53 | 33.44 | 4.54 | 5.06 | 1.06 | 3.29 | 0.4698 | 0.00 | -7.26 | 3.51 | -51.52 | -- | 31.17 | -- |
| Baxter International Inc | 11.77bn | 225.00m | 16.83bn | 60.00k | 74.63 | 2.14 | 12.84 | 1.43 | 0.442 | 0.214 | 23.10 | 15.42 | 0.4105 | 2.91 | 5.42 | 196,133.30 | 0.8198 | 0.1942 | 1.05 | 0.2333 | 38.43 | 38.20 | 2.00 | 0.3674 | 1.09 | 3.81 | 0.6196 | 1,398.94 | 2.12 | 5.94 | 97.15 | -- | 0.982 | 9.71 |
| Align Technology, Inc. | 3.96bn | 441.57m | 17.04bn | 21.61k | 38.90 | 4.33 | 29.26 | 4.30 | 5.87 | 5.87 | 52.63 | 52.76 | 0.6245 | 4.32 | 4.14 | 183,272.50 | 6.96 | 16.34 | 10.39 | 24.14 | 69.98 | 71.72 | 11.15 | 23.16 | 1.14 | -- | 0.00 | 0.00 | 3.42 | 14.45 | 23.09 | 2.15 | -4.46 | -- |
| Hologic Inc | 4.03bn | 789.50m | 18.28bn | 6.99k | 23.71 | 3.56 | 16.64 | 4.54 | 3.32 | 3.32 | 16.97 | 22.09 | 0.4406 | 2.72 | 6.57 | -- | 8.63 | 13.12 | 9.84 | 15.20 | 56.25 | 60.82 | 19.59 | 24.75 | 3.03 | 64.45 | 0.3307 | -- | -0.0025 | 3.66 | 73.14 | -- | 4.30 | -- |
| Insulet Corp | 1.98bn | 420.90m | 18.38bn | 3.00k | 45.55 | 16.44 | 36.83 | 9.26 | 5.75 | 5.75 | 25.96 | 15.94 | 0.7223 | 1.42 | 6.14 | 661,300.00 | 15.32 | 2.71 | 18.56 | 3.14 | 69.36 | 65.81 | 21.22 | 4.28 | 2.80 | 98.71 | 0.5557 | 0.00 | 30.02 | 24.66 | 4,384.78 | 128.77 | -7.63 | -- |
Data as of Nov 22 2024. Currency figures normalised to Revvity Inc's reporting currency: US Dollar USD
56.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2024 | 17.79m | 14.43% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 13.59m | 11.02% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 6.31m | 5.12% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 6.30m | 5.11% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.17m | 5.00% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 5.18m | 4.20% |
| Select Equity Group LPas of 30 Sep 2024 | 5.17m | 4.20% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 30 Sep 2024 | 3.31m | 2.69% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 3.09m | 2.50% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.86m | 2.32% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
